Leqvio (Inclisiran) Cost in Massachusetts 2026

What Does Leqvio Actually Cost in Massachusetts?

Leqvio's Novartis wholesale acquisition cost (WAC) sits at approximately $3,250 per injection, which translates to roughly $6,500 per year or about $540 per month when annualized. Almost nobody pays that number out of pocket. Commercial insurance, manufacturer assistance programs, and 503A compounded alternatives each cut that price substantially for Massachusetts residents.

The published WAC is a starting point for insurance negotiations, not a patient-facing price. Massachusetts participates in the federal 340B Drug Pricing Program, which allows qualifying health systems and federally qualified health centers (FQHCs) to acquire Leqvio at significantly reduced cost and pass some savings to uninsured or underinsured patients. The FDA approved inclisiran on December 22, 2021 under the brand name Leqvio for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL-C lowering on top of maximally tolerated statins 1.

The ORION-10 trial (N=1,561, published NEJM 2020) demonstrated a time-averaged LDL-C reduction of 52% vs. placebo at day 510 2. ORION-11 (N=1,617) confirmed a 49.9% reduction over the same follow-up period 2. These data support why payers, including MassHealth, recognize inclisiran as a clinically meaningful therapy rather than a convenience drug, which directly affects how prior authorization criteria are written.

Patients without any coverage face the full WAC. A telehealth visit with a Massachusetts-licensed prescriber can generate a Leqvio prescription that qualifies for the Novartis patient assistance program (Novartis Patient Assistance Foundation), which provides Leqvio at no cost to patients who meet income thresholds (typically at or below 600% of the federal poverty level) 3.

Does MassHealth (Massachusetts Medicaid) Cover Leqvio?

MassHealth covers Leqvio with prior authorization for members who carry a documented diagnosis of clinical ASCVD or heterozygous familial hypercholesterolemia and who have not reached LDL-C goals on maximally tolerated statin therapy. The prior authorization review mirrors criteria published in the ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction 4.

Prescribers submitting a MassHealth PA for Leqvio typically need to document: the member's most recent LDL-C value (usually above 70 mg/dL for ASCVD, above 100 mg/dL for HeFH), evidence of statin intolerance or maximally tolerated statin plus ezetimibe, and a qualifying ICD-10 diagnosis code (I25.10 for coronary artery disease, E78.01 for FH). MassHealth's PA approval timeline runs up to 72 hours for standard reviews and 24 hours for urgent clinical situations under Massachusetts Executive Office of Health and Human Services guidelines 5.

Once approved, MassHealth members pay $0 to $3.65 in copays depending on their MassHealth plan type (Standard, CarePlus, or a managed care entity such as Tufts Health Together or Boston Medical Center HealthNet Plan). The ACC/AHA 2022 guideline states: "In patients with clinical ASCVD at very high risk whose LDL-C remains above 70 mg/dL despite maximally tolerated statin and ezetimibe, PCSK9 inhibitors or inclisiran are recommended to further reduce LDL-C." 4 That language gives prescribers clear footing for PA appeals when a first submission is denied.

Which Commercial Insurance Plans Cover Leqvio in Massachusetts?

Most major commercial carriers active in Massachusetts, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Tufts Health Plan, and Aetna, place Leqvio on a specialty tier with prior authorization and, in some cases, step therapy requirements. Step therapy typically mandates a trial of a PCSK9 monoclonal antibody (evolocumab or alirocumab) before Leqvio will be approved, though Massachusetts law (M.G.L. c. 176D) requires insurers to grant step-therapy exceptions when a clinician documents a clinical reason 6.

Harvard Pilgrim and Tufts Health Plan have published formulary documents placing inclisiran at Tier 4 specialty with PA. Blue Cross Blue Shield of Massachusetts covers Leqvio under its specialty pharmacy benefit, meaning the drug is dispensed through a designated specialty pharmacy rather than a retail chain, which affects how the Novartis savings card can be applied. Patients should confirm specialty pharmacy designation with their insurer before the prescription is sent, as misrouting can delay treatment by two to four weeks.

After PA approval, out-of-pocket costs under commercial plans vary. A 2023 JAMA Internal Medicine analysis of PCSK9-class PA rates found that 31.4% of initial PA submissions for LDL-lowering biologics were denied on first submission, with approval rates rising to 74% after one appeal 7. Inclisiran faces similar administrative friction. Patients who receive a denial should request a peer-to-peer review between their cardiologist or lipidologist and the plan's medical director; peer-to-peer calls overturn denials at higher rates than written appeals alone.

How the Novartis Leqvio Savings Card Works in Massachusetts

The Novartis Leqvio co-pay savings card (branded as "Leqvio Together") can reduce monthly costs to $0 for eligible commercially insured Massachusetts patients. The card applies to commercial and private insurance only. It does not apply to government-funded programs such as MassHealth, Medicare Part D, or state employee insurance programs classified as government-funded under federal anti-kickback rules 8.

Eligible patients enroll at leqviotogether.com. Once enrolled, the card covers the difference between insurance payment and the patient's out-of-pocket responsibility, up to the program's annual maximum benefit (Novartis has historically set this at $13,000 per calendar year, though terms are subject to change). For a Massachusetts patient on a commercial plan with a $400 specialty copay per injection, the savings card effectively brings that cost to $0 for two injections per year.

Medicare Part D beneficiaries in Massachusetts are excluded from the manufacturer co-pay card under the federal anti-kickback statute, but they may qualify for the Novartis Patient Assistance Foundation program or the Part D Extra Help (Low Income Subsidy) program, which caps drug costs significantly. In 2024, Part D redesign reduced the out-of-pocket cap to $2,000 per year for all Part D drugs, including specialty agents like Leqvio 9. That cap applies in 2025 and 2026 as well under the Inflation Reduction Act provisions.

Is Compounded Inclisiran Legal in Massachusetts?

Compounded inclisiran is legally available through licensed 503A compounding pharmacies in Massachusetts, provided the compounding pharmacy has a valid Massachusetts Board of Pharmacy license and the prescription comes from a state-licensed prescriber for an individually identified patient. Section 503A of the federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare patient-specific preparations that are not on the FDA's list of drugs withdrawn or removed from the market for safety reasons 10.

Inclisiran is not currently on the FDA's list of drugs that may not be compounded. However, the FDA has not added inclisiran to any official "bulk drug substance" list that would explicitly authorize its inclusion in 503A preparations. This is a legal gray area. The FDA's 2023 draft guidance on compounding complex drug products notes that biologics and RNA-based drugs present distinct manufacturing challenges, and it cautions that compounded versions may not have the same bioavailability or stability profile as the FDA-approved product 11.

Massachusetts Board of Pharmacy regulations at 247 CMR 9.00 require that 503A compounders dispense only on a patient-specific prescription and maintain quality assurance records. Patients considering compounded inclisiran should ask the pharmacy for a Certificate of Analysis (COA) from an independent third-party laboratory confirming potency and sterility. No peer-reviewed head-to-head clinical trial has compared compounded inclisiran to Leqvio in a controlled setting.

The cost difference is significant. Compounded inclisiran from Massachusetts 503A pharmacies has been quoted at prices far below the Novartis WAC, with some telehealth-affiliated pharmacies listing prices between $200 and $500 per injection dose, though pricing varies considerably. Patients should verify the pharmacy's accreditation with the Pharmacy Compounding Accreditation Board (PCAB) before purchasing.

Can a Telehealth Provider Prescribe Leqvio in Massachusetts?

Telehealth prescribing of Leqvio is legal in Massachusetts for established patients who have had at least one prior clinical encounter. Massachusetts General Law c. 112, s. 5 governs licensure for telehealth prescribers. Following the COVID-19 public health emergency, Massachusetts permanently authorized telehealth prescribing of non-controlled substances without a prior in-person visit when clinically appropriate, under guidance issued by the Massachusetts Board of Registration in Medicine 12.

A telehealth cardiologist, primary care physician, or endocrinologist licensed in Massachusetts may review lipid panel results, confirm an ASCVD or FH diagnosis, assess statin history, and issue a Leqvio prescription during a video or phone visit. The prescriber must document the clinical basis for the prescription in the patient's medical record. Inclisiran is not a controlled substance, so it does not trigger the DEA's Ryan Haight Act in-person visit requirements 13.

For patients using HealthRX or similar telehealth platforms, the prescriber can route the prescription to a patient's preferred specialty pharmacy or, where clinically appropriate and legally permissible, to a licensed 503A compounder. The first Leqvio injection is typically administered in a clinical setting because the drug is given as a subcutaneous injection by a healthcare provider, though Massachusetts does not prohibit self-administration by a trained patient.

Clinical Rationale for Inclisiran in ASCVD and FH

Inclisiran works through RNA interference. It targets PCSK9 messenger RNA in hepatocytes, reducing PCSK9 protein synthesis and allowing LDL receptors to remain on the cell surface longer, clearing more LDL-C from circulation 14. This mechanism differs from PCSK9 monoclonal antibodies (evolocumab, alirocumab), which neutralize circulating PCSK9 protein rather than suppressing its production.

The ORION-9 trial (N=482, NEJM 2020) tested inclisiran specifically in patients with heterozygous familial hypercholesterolemia 15. At day 510, inclisiran produced a time-averaged LDL-C reduction of 47.9% vs. placebo (P<0.001), with 48% of inclisiran-treated patients reaching an LDL-C below 70 mg/dL compared with 2% in the placebo group. The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease notes: "Patients with LDL-C levels that remain above goal despite maximally tolerated statin therapy are candidates for nonstatin therapies, including PCSK9 inhibitors." 16 Inclisiran fits this therapeutic space.

The ORION-4 outcomes trial (NCT03705234), a 5-year randomized controlled trial enrolling over 15,000 patients with established ASCVD, is ongoing as of 2025 and is expected to report primary cardiovascular event data 17. Prescribers and payers in Massachusetts are watching ORION-4 because cardiovascular outcomes data would likely expand coverage criteria and reduce PA denial rates.

Adverse events in ORION-10 and ORION-11 were generally mild. Injection-site reactions occurred in 4.7% of inclisiran-treated patients vs. 0.8% placebo (P<0.001) 2. No excess of serious adverse events was observed vs. placebo across all ORION trials combined. The drug has no known drug-drug interactions via cytochrome P450 pathways because it acts intracellularly via RNA interference rather than through hepatic metabolic enzymes 1.

Comparing Inclisiran to PCSK9 Monoclonal Antibodies on Cost and Coverage in Massachusetts

PCSK9 monoclonal antibodies (evolocumab/Repatha, alirocumab/Praluent) have been on the Massachusetts market since 2015 and 2015 respectively, meaning more commercial plans have established coverage pathways for them than for inclisiran. Repatha's WAC is approximately $5,850 per year; Praluent's WAC is approximately $5,850 per year as well after Sanofi price reductions. Leqvio's annual WAC of approximately $6,500 sits slightly above both after accounting for its twice-yearly administration.

The dosing frequency difference matters practically. Evolocumab and alirocumab require injections every two weeks or monthly. Inclisiran requires only two injections per year after the initial loading sequence (Day 1, Day 90, then every 180 days). A 2023 Circulation paper modeling adherence across PCSK9-lowering therapies found that less frequent dosing correlated with a 22% higher persistence rate at 12 months compared with biweekly regimens 18. Patients who struggle with chronic injection schedules may find inclisiran's twice-yearly cadence easier to maintain.

From a Massachusetts insurance perspective, many PA templates that were originally written for PCSK9 monoclonal antibodies now include inclisiran as an alternative agent. Step therapy policies vary by plan. Patients denied coverage for inclisiran on step-therapy grounds should document that their prescriber selected inclisiran specifically because of the reduced dosing burden, a distinct clinical reason that Massachusetts law allows as a step-therapy exception under M.G.L. c. 176D 6.

What Happens If MassHealth Denies Prior Authorization for Leqvio?

A MassHealth prior authorization denial for Leqvio triggers the member's right to a fair hearing under 130 CMR 610.000. The appeal must be filed within 30 days of the denial notice. During the appeal, MassHealth must maintain continuity of coverage for any drug the member was previously receiving. For Leqvio specifically, where the member was not previously on the drug, the 30-day appeal window means the prescriber must act quickly to submit additional clinical documentation.

Effective appeals include: a letter of medical necessity from a board-certified cardiologist or lipidologist, the most recent lipid panel, documentation of statin and ezetimibe trials with LDL-C values before and after each trial, and peer-reviewed citations supporting inclisiran's efficacy in the specific patient population. The ORION-10 and ORION-11 data 2 and the ORION-9 HeFH data 15 are directly relevant for this documentation.

The National Lipid Association's 2023 patient advocacy toolkit recommends attaching the patient's 10-year ASCVD risk calculation (using the Pooled Cohort Equation available at tools.acc.org) to every PA submission for LDL-lowering biologics, as this numerical documentation reduces denial rates in retrospective audits of payer decisions 19. Massachusetts also has an independent external review process through the Office of Patient Protection for commercial plan denials, which runs concurrently with the internal appeal and typically resolves within 45 days 6.

A Practical Decision Framework for Massachusetts Patients Seeking Leqvio

The following four-step path covers the most common scenarios for Massachusetts residents:

Step 1: Confirm insurance type. Commercial insurance, MassHealth, Medicare Part D, or uninsured each leads to a different cost pathway. Commercial patients should immediately request the Novartis savings card enrollment link from their prescriber or specialty pharmacy.

Step 2: Submit PA documentation proactively. Do not wait for a denial. Attach a lipid panel dated within 90 days, a statin trial history table, and the relevant ORION trial citation 2 at the time of initial PA submission. Proactive documentation reduces the denial rate in the first submission.

Step 3: If denied, escalate within 72 hours. Request a peer-to-peer between your cardiologist and the plan's medical director. Massachusetts law (M.G.L. c. 176D) requires the plan to make this call available within two business days of request 6.

Step 4: If appeals fail, evaluate compounded inclisiran. Confirm the 503A pharmacy holds a current Massachusetts Board of Pharmacy license, request a COA from an independent lab, and document the clinical rationale in the medical record. Telehealth prescribers licensed in Massachusetts can route to a 503A compounder if clinically appropriate 12.

The ACC/AHA recommends a target LDL-C below 70 mg/dL for very high-risk ASCVD patients and below 55 mg/dL for those who have had a second cardiovascular event 4. If inclisiran is the agent selected to reach those targets, the steps above give Massachusetts patients the most direct route to obtaining it at the lowest possible cost.